Nexalin TechnologyNXL
Market Cap: $7.52M
About: Nexalin Technology Inc designs and develops innovative neurostimulation products to uniquely and effectively help combat the ongoing global mental health epidemic. The company has developed an easy-to-administer medical device referred to as Generation 1 or Gen-1 that utilizes bioelectronic medical technology to treat anxiety and insomnia, without the need for drugs or psychotherapy. Its original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit waveform at 4 milliamps during treatment and are presently classified by the U.S. Food and Drug Administration (FDA) as a Class II device.
Employees: 6
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
425% more capital invested
Capital invested by funds: $88.9K [Q1] → $467K (+$378K) [Q2]
400% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 2
160% more funds holding
Funds holding: 5 [Q1] → 13 (+8) [Q2]
100% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 1
2.79% more ownership
Funds ownership: 0.85% [Q1] → 3.64% (+2.79%) [Q2]
Research analyst outlook
We haven’t received any recent analyst ratings for NXL.